UNSPSC 51372023: Butorphanol tartrate

This classification denotes an opioid analgesic with the molecular formula C21H29NO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2L7I72RUHN, chemically known as l-n-cyclobutylmethyl-3,14-dihydroxymorphinan tartrate salt but more generally known as butorphanol tartrate, which bears US NIH Compound Identifier 5462346. European Medicines Agency schedules Butorphanol tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00920MIG.

UNSPSC 51372023 Butorphanol tartrate is a Commodity code that covers pharmaceutical active ingredients and finished pharmaceutical products procured by state and local health agencies, including naloxone and other emergency medications, as well as generic multi-source pharmaceuticals and over-the-counter products distributed through state and county health systems. State and local governments buy under this code primarily through health departments, county community health programs, and state Medicaid and employee health benefit programs that need to stock emergency response medications, community health initiatives, and pharmaceutical supplies for state facilities and participating jurisdictions. The issuing bodies range from county health departments managing direct procurement of emergency medications to state health and human services commissions conducting market intelligence and cooperative purchasing alliances that aggregate demand across multiple state and local entities. Cooperative purchasing vehicles, particularly multistate alliances, structure much of the pharmaceutical procurement activity by consolidating buying power and establishing framework agreements with manufacturers and wholesalers.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with response deadline March 26, 2026, requiring vendors to supply through authorized wholesalers with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness.